Seattle Genetics Receives Orphan Drug Designations in US, Europe

Seattle Genetics, Inc. announced that SGN-35 has been granted orphan drug designation by the European Medicines Agency for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma and by the U.S. Food and Drug Administration for the treatment of ALCL.
RTTNews